Browse News

Found 510 articles

• New "AI Doctor" Predicts Hospital Readmission and Other Health Outcomes

  6/7/2023

  An artificial intelligence computer program can read physicians' notes to accurately estimate patients' risk of death, length of hospital stay, and other factors important to care.

• Mirati Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023

  6/1/2023

  Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, will participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023 on June 15 at 8:40 a.m. P.T. / 11:40 a.m. E.T.

• Mirati To Encore Compelling Clinical Data Demonstrating Adagrasib's Potential as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors at 2023 ASCO Annual Meeting

  5/30/2023

  Mirati Therapeutics, Inc.®  (NASDAQ: MRTX), a commercial stage biotechnology company, today announced presentations and posters to be shared at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrating the utility of adagrasib across multiple tumor types.

• 

  Mirati’s Sitravatinib Fails in Phase III Lung Cancer Trial, Nixes Development

  5/25/2023

  The investigational kinase inhibitor failed to improve overall survival in the SAPPHIRE study of patients with non-squamous non-small cell lung cancer, causing Mirati to discontinue its development.

• Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib

  5/25/2023

  Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced updated data from Part A of the ongoing registration-directed RAMP 201 trial evaluating the safety and efficacy of avutometinib alone and in combination with defactinib among patients with recurrent low-grade serous ovarian cancer.

• Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO®

  5/24/2023

  Mirati Therapeutics, Inc.®, a commercial-stage oncology company, announced that the SAPPHIRE study did not meet its primary endpoint of overall survival at the final analysis.

• Verastem Oncology Appoints Karin Tollefson, PhD, to Board of Directors

  5/16/2023

  Verastem Oncology today announced the appointment of Karin Tollefson to its Board of Directors, effective May 15, 2023.

• Aadi Bioscience Announces Financial Results and Operational Update for the First Quarter 2023 and Provides Update on PRECISION 1 Tumor Agnostic Trial

  5/10/2023

  Aadi Bioscience, Inc. today announced financial results for the first quarter of 2023 and provided an initial update on the tumor-agnostic PRECISION 1 trial, a registration-directed Phase 2 study of nab-sirolimus in patients with solid tumors with pathogenic inactivating alterations in TSC1 or TSC2 genes.

• Mirati Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Updates

  5/9/2023

  Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the first quarter 2023 along with recent pipeline and corporate updates.

• Verastem Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

  5/9/2023

  Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the first quarter ending March 31, 2023, and highlighted recent progress.

• Mirati Therapeutics and Sarah Cannon Research Institute Announce Strategic, Community Site Focused Partnership to Increase Diversity in Oncology Clinical Studies

  5/8/2023

  Mirati Therapeutics, Inc.® and Sarah Cannon Research Institute announced a strategic partnership aimed at increasing diversity in clinical study recruitment practices.

• Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - May 5, 2023

  5/5/2023

  Mirati Therapeutics, Inc. today announced that the company granted equity awards to 2 new employees with a grant date of May 1, 2023, as equity inducement awards outside of the company's 2022 Equity Incentive Plan (but under the terms of the company's Inducement Plan) and material to the employees' acceptance of employment with the company.

• Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs

  5/2/2023

  Incyte (Nasdaq:INCY) today reports 2023 first quarter financial results, and provides a status update on the Company’s clinical development portfolio.

• Mirati Therapeutics to Participate at the Bank of America Securities 2023 Health Care Conference

  4/27/2023

  Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, will participate at the Bank of America Securities 2023 Health Care Conference on May 11 at 10:00 a.m. P.T. / 1:00 p.m. E.T. Ben Hickey, chief commercial officer, will represent the company in a fireside chat at the conference.

• Journal of Clinical Oncology Publishes Rapid Communication Featuring Updated Clinical Data for Adagrasib as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors

  4/26/2023

  Mirati Therapeutics, Inc.® (NASDAQ: MRTX) announced today the Journal of Clinical Oncology published in a Rapid Communication data indicating adagrasib, a potent and selective KRASG12C inhibitor, is well tolerated and demonstrates meaningful clinical activity in patients with pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), and other solid tumors harboring a KRASG12C mutation.

• New Data from Interim Analysis of Verastem Oncology’s RAMP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at the American Society of Clinical Oncology Annual Meeting

  4/26/2023

  Verastem Oncology, (Nasdaq: VSTM) today announced that an abstract highlighting updated interim results from Part A of the ongoing Phase 2, registration-directed RAMP 201 trial evaluating avutometinib (VS-6766) and defactinib in patients with low-grade serous ovarian cancer (LGSOC) has been selected for a presentation in a Poster Discussion Session at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2–6, 2023 in Chicago, IL.

• Mirati Therapeutics® to Report First Quarter 2023 Financial Results and Recent Corporate Updates on May 9, 2023

  4/25/2023

  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, will announce financial results for the first quarter 2023 along with recent corporate updates on May 9, 2023.

• 

  Lilly Seeks First-Line KRAS Treatment with AACR Data Release

  4/19/2023

  Lilly investigators said they hoped to differentiate their Phase I candidate from the competitive KRAS space by making it the first to gain approval as a first-line treatment.

• Mirati To Present Research at the AACR Annual Congress for Two Potentially First-in-Class Clinical Stage Programs

  4/3/2023

  Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced a presentation demonstrating in preclinical models the ability of MRTX0902, a selective and potent SOS1 inhibitor, to enhance anti-tumor activity and overcome acquired resistance in combination with either adagrasib, a potent and selective KRASG12C inhibitor, or an epidermal growth factor receptor (EGFR)  inhibitor (e.g. osimertinib).

• Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Corporate Update

  3/28/2023

  Aadi Bioscience, Inc. today provided a corporate update and announced financial results for the fourth quarter and full-year 2022.